Wee1 kinase as a target for cancer therapy

被引：253

作者：

Do, Khanh ^{[1
]}

Doroshow, James H. ^{[1
,2
]}

Kummar, Shivaani ^{[1
,2
]}

机构：

[1] NCI, Ctr Canc Res, Bethesda, MD 20892 USA

[2] NCI, Div Canc Treatment & Diag, Bethesda, MD 20892 USA

来源：

CELL CYCLE | 2013年 / 12卷 / 19期

关键词：

cyclin-dependent kinase; G2; checkpoint; cell cycle; DNA damage; MK; 1775; CYCLIN-DEPENDENT KINASES; HOMOLOGOUS RECOMBINATION; CHECKPOINT CONTROL; DNA; INHIBITION; MK-1775; HSP90; CELLS; CHK1; PHOSPHORYLATION;

D O I：

10.4161/cc.26062

中图分类号：

Q2 [细胞生物学];

学科分类号：

071013 [干细胞生物学];

摘要：

Wee1, a protein kinase, regulates the G(2) checkpoint in response to DNA damage. Preclinical studies have elucidated the role of wee1 in DNA damage repair and the stabilization of replication forks, supporting the validity of wee1 inhibition as a viable therapeutic target in cancer. MK-1775, a selective and potent small-molecule inhibitor of wee1, is under clinical development as a potentiator of DNA damage caused by cytotoxic chemotherapies. We present a review of the role of wee1 in the cell cycle and DNA replication and summarize the clinical development to date of this novel class of anticancer agents.

引用

页码：3159 / 3164

页数：6

共 46 条

[1]

A ROLE FOR HSP90 IN CELL-CYCLE CONTROL - WEE1 TYROSINE KINASE-ACTIVITY REQUIRES INTERACTION WITH HSP90 [J].